Cadent Capital Advisors LLC Grows Stake in iShares U.S. Pharmaceuticals ETF $IHE

Cadent Capital Advisors LLC lifted its holdings in iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) by 1,298.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 35,010 shares of the company’s stock after buying an additional 32,507 shares during the quarter. Cadent Capital Advisors LLC’s holdings in iShares U.S. Pharmaceuticals ETF were worth $3,519,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Bank of America Corp DE raised its position in shares of iShares U.S. Pharmaceuticals ETF by 2.8% in the 1st quarter. Bank of America Corp DE now owns 456,606 shares of the company’s stock worth $39,579,000 after purchasing an additional 12,565 shares during the last quarter. Insight Wealth Strategies LLC grew its holdings in shares of iShares U.S. Pharmaceuticals ETF by 3.3% during the second quarter. Insight Wealth Strategies LLC now owns 122,642 shares of the company’s stock valued at $12,055,000 after buying an additional 3,950 shares during the last quarter. Cetera Investment Advisers raised its holdings in iShares U.S. Pharmaceuticals ETF by 675.4% in the 1st quarter. Cetera Investment Advisers now owns 109,471 shares of the company’s stock worth $9,489,000 after acquiring an additional 95,353 shares during the last quarter. Tidal Investments LLC bought a new position in iShares U.S. Pharmaceuticals ETF in the 2nd quarter valued at approximately $3,716,000. Finally, AdvisorNet Financial Inc boosted its stake in iShares U.S. Pharmaceuticals ETF by 2.5% during the 1st quarter. AdvisorNet Financial Inc now owns 40,993 shares of the company’s stock valued at $3,553,000 after purchasing an additional 983 shares during the last quarter.

iShares U.S. Pharmaceuticals ETF Stock Performance

Shares of IHE stock traded up $1.37 during mid-day trading on Friday, hitting $100.23. The company’s stock had a trading volume of 109,617 shares, compared to its average volume of 164,446. iShares U.S. Pharmaceuticals ETF has a 52-week low of $72.94 and a 52-week high of $108.66. The stock has a market cap of $1.63 billion, a price-to-earnings ratio of 17.75 and a beta of 0.47. The business has a 50-day moving average price of $102.73 and a 200 day moving average price of $96.04.

iShares U.S. Pharmaceuticals ETF Profile

iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.